Effect of systemic glutathione depletion by buthionine sulfoximine on sensitivity of murine bladder cancer to cytotoxic agents.
The effect of systemic glutathione (GSH) depletion on sensitization of bladder cancer cells to various antineoplastic agents was investigated using murine model, MBT-2. Subcutaneous injection(s) of buthionine sulfoximine (BSO) significantly depleted the GSH content in the tumor and organs. BSO pretreatment produced significant enhancement in the antitumor effect of cyclophosphamide (CY), though it failed to sensitize the tumors to doxorubicin hydrochloride (Adriamycin), cisplatin, mitomycin C, JM-8, methotrexate, vinblastine, and tumor necrosis factor. Mice tolerated cytotoxic agents alone and in combination with BSO except for cisplatin in combination with BSO. A 29 percent (4/14) mortality rate was observed in mice treated with BSO and divided schedule of cisplatin.
Lee
K E
KE
Urology Department, University of Rochester School of Medicine, New York.
Mayer
R D
RD
Cockett
A T
AT
D000818:Animals; D000963:Antimetabolites / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D019328:Buthionine Sulfoximine; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D005260:Female; D005978:Glutathione / Q000032:analysis / Q000037:antagonists & inhibitors*; D007668:Kidney / Q000032:analysis; D008099:Liver / Q000032:analysis; D008168:Lung / Q000032:analysis; D008717:Methionine Sulfoximine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D051379:Mice; D008809:Mice, Inbred C3H; D009206:Myocardium / Q000032:analysis; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000963:Antimetabolites; D000970:Antineoplastic Agents; D008717:Methionine Sulfoximine; D019328:Buthionine Sulfoximine; D005978:Glutathione